Q1 2026 Aptargroup Inc Earnings Call Transcript
Key Points
- AptarGroup Inc (ATR) reported an 11% increase in sales, with core sales remaining flat after adjusting for currency effects and acquisitions.
- The Pharma segment showed strong demand in injectables, with a 20% increase in core sales, driven by elastomeric components for GLP-1 biologics and antithrombotics.
- Consumer Healthcare core sales increased by 4%, supported by growth in eyecare and nasal decongestant products.
- The Beauty segment saw a 3% increase in core sales, with strong demand for prestige fragrance pumps and color cosmetics.
- AptarGroup Inc (ATR) maintained a strong balance sheet, ending the quarter with a cash balance of $223 million and a leverage ratio of 1.43.
- Pharma segment's core sales decreased by 1% due to less favorable product mix and a decline in emergency medicine sales.
- Adjusted EBITDA margin declined to 19.2% from 20.7% in the prior year, primarily due to less favorable product mix and operational challenges in beauty and closures.
- The Closures segment experienced a 270 basis point decline in adjusted EBITDA margin due to maintenance issues and temporary plant closures caused by extreme weather conditions.
- Adjusted earnings per share decreased to $1.19 from $1.30 in the prior year, impacted by higher depreciation, amortization expenses, and interest expenses.
- The company faced ongoing litigation with ARS Pharmaceuticals, which continues to progress and adds legal expenses.
Ladies and gentlemen, thank you for standing by, and welcome to Aptar's 2026 first quarter results conference call.
(Operator Instructions)
Introducing today's conference call is Ms. Mary Skafidas, Senior Vice President, Investor Relations and Communications. Please go ahead.
Hello, everyone, and thanks for being with us today. Joining me on today's call are Stephan Tanda, our President and CEO; Vanessa Kanu, Executive Vice President and CFO, and Gael Touya, our CEO Designate; and President of Aptar Pharma. Our press release and accompanying slide deck have been posted on our website under the Investor Relations page.
During this call, we will be discussing certain non-GAAP financial measures. These measures are reconciled to the most directly comparable GAAP financial measure and the reconciliations are set forth in the press release. Please refer to the press release disseminated yesterday for the reconciliations of non-GAAP measures to the most comparable GAAP measure discussed
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
